Introduction: A major clinical challenge in treating allergic contact dermatitis (ACD) is that the first line of treatment is based on the use of corticosteroids. In this study, we aimed to develop a formulation that is devoid of steroids.
Methods: We used mouse ears treated with dinitrofluorobenzene (DNFB) to induce ACD. The efficacy of the test formulation to ameliorate and to prevent induced ACD was determined.
Results: To treat this experimentally induced ACD, we developed a formulation containing BIPxine (a mixture of Rosa moschata and Croton lechleri (antioxidants) and Aloe vera and D-panthenol (moisturizers), and hydroglycolic solutions of disodium cromoglycate. Our results show that clear inhibition of ACD took place. The target of this formulation was PAR-2, TRPV4, and other mediators of the inflammatory and pain responses. However, this formulation must be evaluated in other models besides the mouse to confirm its effectiveness.
Conclusion: The formulation presented here may provide new ACD therapies that do not involve the use of corticosteroids.
Patch testing reactions can be difficult to interpret in patients with skin of color (higher Fitzpatrick skin types [FSTs]) due to limited erythema or vesiculation. Missed reactions may lead to prolonged allergic contact dermatitis duration and prevent disease clearance in this population. To compare the frequency of borderline patch test reactions in patients with different FSTs (I, II, III, IV, V, VI).
Panthenol, a vitamin B5 derivative, is a key precursor in the synthesis of fatty acids that maintain epithelial function. Its ability to aid in moisturization, skin barrier restoration, and wound healing has led to its frequent incorporation into personal care products and pharmaceuticals-many of which are marketed to be hypoallergenic. While contact allergy to panthenol is rather uncommon, rates of positive reactions are on the rise, increasing from 0.
From the Department of Stomatognathic Function and Occlusal Reconstruction, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Eosinophilia is a common laboratory finding with a broad differential diagnosis. Eosinophilia can be classified as primary, secondary, or idiopathic hypereosinophilic syndrome (HES). Primary eosinophilia results from a clonal disorder of eosinophils, while secondary eosinophilia is reactive to a variety of underlying conditions, such as allergic diseases, infections, and drug reactions.
Background/objectives: Eyelid allergic contact dermatitis (ACD) attributed to ophthalmic medications is often underreported, which can result in poor outcomes. Patch testing for eyelid ACD requires up-to-date knowledge of potential allergens. The aim of this study was to investigate allergens in ophthalmic medicaments in New Zealand.
